Jeremy L. Stigall serves as Chief Business Officer at ClearPoint Neuro, Inc., a leading developer of innovative platforms for precise drug delivery and therapy guidance in the brain. In this role, he drives the company's business development, strategic partnerships, and commercialization efforts, leveraging the ClearPoint Neuro Navigation System to advance minimally invasive neurosurgical procedures. Stigall plays a pivotal role in expanding market access, forging collaborations with pharmaceutical and biotech partners, and scaling the adoption of ClearPoint's technologies for applications in gene therapy, biologics delivery, and beyond. With over two decades of experience in the medical device industry, Stigall brings deep expertise in neuromodulation and neurotechnology. Prior to joining ClearPoint Neuro in 2021, he was Vice President of Strategy and Business Development at Medtronic's Neuromodulation operating unit, where he led global initiatives that generated hundreds of millions in annual revenue growth through innovative partnerships, product launches, and market expansions in deep brain stimulation (DBS), spinal cord stimulation, and sacral neuromodulation. Earlier in his career at Boston Scientific Corporation, he held senior positions in marketing and business development, contributing to the successful commercialization of next-generation neuromodulation therapies. Stigall's achievements include spearheading transformative deals, such as Medtronic's strategic alliances in brain-computer interfaces and precision therapies, earning him recognition as a key architect of growth in high-stakes neuro markets. Holding an MBA from the University of Minnesota Carlson School of Management and a BS in Biomedical Engineering from Washington University in St. Louis, he combines technical acumen with strategic vision to position ClearPoint Neuro at the forefront of neurologic innovation.